Evidence map›Paper›PMID 35943655›Full record

ReviewMolecular and cellular biochemistry2023

Short-chain fatty acids: possible regulators of insulin secretion.

Nur Suraya Ashikin Rosli, Shafinaz Abd Gani, Mohd Ezuan Khayat, Uswatun Hasanah Zaidan, Amin Ismail, Mohd Badrin Hanizam Abdul Rahim

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular and cellular biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Article
  11. Dietary approaches for normalizing dysbiosis induced by high-fat, obesogenic diets.Current opinion in clinical nutrition and metabolic care · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nur Suraya Ashikin RosliDepartment of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Shafinaz Abd GaniDepartment of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Mohd Ezuan KhayatDepartment of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Uswatun Hasanah ZaidanDepartment of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Amin IsmailDepartment of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
Mohd Badrin Hanizam Abdul RahimDepartment of Biochemistry, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Serdang, Malaysia. badrin@upm.edu.my.ORCID http://orcid.org/0000-0001-5291-0020
Universiti Putra Malaysia · MY

Funding

Fundamental Grant Research Scheme Malaysia 04-01-18-1930FR (Vot No. 5540055)
6 · The paper itself

Abstract

The benefits of gut microbiota-derived short-chain fatty acids (SCFAs) towards health and metabolism have been emerging since the past decade. Extensive studies have been carried out to understand the mechanisms responsible in initiating the functionalities of these SCFAs towards body tissues, which greatly involves the SCFA-specific receptors free fatty acid receptor 2 (FFAR2) and free fatty acid receptor 3 (FFAR3). This review intends to discuss the potential of SCFAs particularly in regulating insulin secretion in pancreatic β-cells, by explaining the production of SCFAs in the gut, the fate of each SCFAs after their production, involvement of FFAR2 and FFAR3 signalling mechanisms and their impacts on insulin secretion. Increased secretion of insulin after SCFAs treatments were reported in many studies, but contradicting evidence also exist in several other studies. Hence, no clear consensus was achieved in determining the true potential of SCFA in regulating insulin secretion. In this review, we explore how such differences were possible and hopefully be able to shed some perspectives in understanding SCFAs-signalling behaviour and preferences.

Indexed as

Fatty Acids, NonesterifiedReceptors, G-Protein-CoupledFatty Acids, VolatileInsulinInsulin SecretionFatty Acids, NonesterifiedFatty Acids, VolatileInsulinReceptors, G-Protein-CoupledFFAR2FFAR3Glucose-stimulated insulin secretion (GSIS)G-protein coupled receptor (GPCR)Gαq/11-signalling mechanismShort-chain fatty acids (SCFAs)

Identifiers

PMID35943655
OpenAlexW4290771574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.